Sign in

NCT07569016Recruiting

BIS-Guided Sedation Versus Standard Clinical Sedation During Elective Electrical Cardioversion for Atrial Fibrillation

Bispectral Index-Guided Sedation Versus Standard Clinical Assessment-Guided Sedation During Elective Electrical Cardioversion for Atrial Fibrillation: A Prospective, Single-Center, Randomized Controlled, Assessor-Blinded Trial

Source: ClinicalTrials.gov · Last updated 15 May 2026

Brief summary (registry, in English)

Electrical cardioversion (ECV) is a standard procedure used to restore normal heart rhythm in patients with atrial fibrillation (AF) by delivering a brief electrical shock to the heart. Because the procedure is painful and distressing, patients receive sedation - a controlled state of reduced consciousness - using short-acting intravenous medications. However, the optimal depth of sedation for ECV has not been well defined: too deep may cause breathing problems and low blood pressure, while too light may result in pain, awareness, or patient movement during the shock. Bispectral index (BIS) monitoring is a non-invasive technology that continuously measures brain activity using an EEG sensor placed on the forehead, generating a numerical score from 0 (no brain activity) to 100 (fully awake). BIS scores between 61 and 80 correspond to moderate sedation, which preliminary observations suggest may be sufficient for ECV without the risks associated with deeper sedation. This randomized controlled trial will compare two approaches to sedation monitoring during elective ECV for AF: * Group 1 (BIS Group): Sedation is guided by BIS monitoring, targeting a score of 61-80. * Group 2 (Control Group): Sedation is guided by standard clinical assessment (loss of response to verbal commands and eyelash reflex), with BIS recorded but not visible to the treating team. Both groups will receive the same medications (propofol and fentanyl). The primary outcome is how quickly patients recover after the procedure, measured by the Modified Aldrete Score - a standard clinical recovery assessment tool. Secondary outcomes include patient and physician satisfaction, procedural pain, risk of awareness during the procedure, cardioversion success rate, hemodynamic stability, and complication rates. The trial will enroll 60 adult patients at Istanbul University-Cerrahpasa Cardiology Institute. Findings are expected to provide evidence-based guidance for standardizing sedation protocols during ECV.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
60 (estimated)
First submitted
12 Apr 2026
Start date
13 Apr 2026
Primary completion date
15 Jun 2026
Lead sponsor
Istanbul University - Cerrahpasa
NCT number
NCT07569016

What you commit to

  • Study type: Interventional
  • Planned participants: 60
  • From 13 Apr 2026 to the primary completion date, 15 Jun 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Severe obstructive sleep apnea requiring CPAP or BiPAP therapy
  • Prior participation in this trial

Other illness

  • Known allergy or contraindication to propofol or fentanyl, or their excipients (soy, egg)
  • Decompensated heart failure (NYHA functional class IV)
  • Baseline oxygen saturation \<94% or active chronic obstructive pulmonary disease
  • Active psychiatric illness or cognitive impairment precluding questionnaire completion

Lab values

  • Severe hepatic impairment (transaminases \>3× upper limit of normal) or severe renal impairment (eGFR \<30 mL/min/1.73m²)

Other

  • Hemodynamic instability (systolic blood pressure \<90 mmHg or symptomatic hypotension)
  • Anticipated difficult airway (modified Mallampati classification class III or IV)
  • Pregnancy or breastfeeding
  • Alcohol or substance use within the preceding 24 hours

Who the study is looking for

  • Age ≥18 years
  • Documented atrial fibrillation with indication for elective electrical cardioversion
  • American Society of Anesthesiologists (ASA) physical status class I, II, or III
  • Left ventricular ejection fraction ≥30% on echocardiography
  • Adequate anticoagulation: INR ≥2.0, OR ≥3 weeks of therapeutic anticoagulation, OR absence of left atrial thrombus confirmed by transesophageal echocardiography
  • Ability and willingness to provide written informed consent

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Istanbul University-Cerrahpaşa, Cardiology Institute
Coordinator of this site? Confirm its status
IstanbulTurkey (Türkiye)Recruiting

This page is information, not medical advice. Discuss any trial with your doctor.